Reducing heart damage and improving function after a heart attack using targeted drugs.
Official title: Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.
Funded at Young Therapeutics, LLC · NIH-11068139 · Data updated 2026-11-12
This study is testing two new heart-protecting drugs, YT-002 and YT-004, in pigs to see how well they work after a heart attack, with hopes of eventually helping people keep their hearts healthy.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Young Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 1, 2025 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,488,899 |
| NIH project number | 2R44HL160338-02 |
| Project ID | NIH-11068139 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced a myocardial infarction or are at high risk for heart attacks.
✕Less likely to help
Patients who have not had a heart attack or do not have cardiovascular issues may not benefit from this research.
What this research studies
This research focuses on developing two new drugs, YT-002 and YT-004, that aim to protect heart tissue and maintain heart function after a heart attack. The study will involve testing these drugs in a pig model to understand how they work in the body and their long-term effects on heart health. Researchers will optimize the drug formulations for better stability and delivery, and conduct detailed studies to assess how the drugs are absorbed and how they affect heart function over time. The ultimate goal is to gather enough evidence to support future human trials.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce heart damage and improve recovery after heart attacks.
How similar studies have gone: Previous research has shown promise in using targeted therapies for cardiac protection, suggesting potential success for this approach.
Where this research is happening
-
Young Therapeutics, LLC
Philadelphia, United States Active
Researchers
- Principal investigator: Young, Lindon H — Young Therapeutics, LLC
- Study coordinator: Young, Lindon H
Related research
Other NIH-funded projects on the same topics.
-
Anti-inflammatory signaling of a key protein in heart attack recovery
A study in people who have had a heart attack is exploring how a macrophage protein called Tristetraprolin may reduce inflammation and help protect heart tissue.
-
Targeting RIPK3 to reduce heart damage after a heart attack
This grant studies a specific cell-death pathway (RIPK3) to protect the heart after a heart attack, with the goal of reducing damage and improving recovery.
-
mRNA lipid nanoparticles to help heart attack patients grow healthier blood vessels
A heart-attack study tests a new treatment that uses messenger RNA delivery with tiny fat bubbles to promote normal blood vessel growth in damaged heart tissue.
-
Targeted nanotherapy to calm inflammation, grow new blood vessels, and prevent scarring after a heart attack
A new treatment approach uses engineered secretions from immune cells delivered early after a heart attack to reduce inflammation, promote blood vessel growth, and limit scarring to protect heart function.
-
Why heart attacks and strokes affect people differently across places and races
This project follows adults across the U.S. to see how lifelong social and neighborhood factors shape heart attacks, heart failure, and recovery, with attention to Black adults and regions with high disease rates.
-
Real-time multi-lead ECG from wearables to help detect heart attacks early
A new AI-based approach uses everyday wearable sensors to turn simple PPG signals into multi-lead ECG data to monitor for heart attacks in real time, even outside the clinic.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.